Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

NCT: NCT03838445 · ACTIVE_NOT_RECRUITING

NCT IDNCT03838445
StatusACTIVE_NOT_RECRUITING
Start Date2020-02-14
SponsorV-Wave Ltd (INDUSTRY)
First posted
Last updated

Brief Summary

The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑